EUVIMEDEUVIMED entdecken
Open Access

Real-World Efficacy and Safety of Oral Tofacitinib in Patients with Refractory Moderate to Severe Atopic Dermatitis: A Multicenter Retrospective Study

Sandipan Dhar, Abhishek De, Aarti Sarda, Kiran Godse, Koushik Lahiri

Indian Journal of Dermatology · 2024-07 · 69 (4) · 292-295

DOI: 10.4103/ijd.ijd_843_22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Dermatology, online erschienen am 19.08.2024. Verfasst von Sandipan Dhar und 4 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Pediatric Dermatology, Institute of Child Health, Kolkata, West Bengal, India. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) has a complex etiology that includes Th2 polarization, which is accompanied by the cytokines IL4, IL-5, IL-13, and IL-31, as well as Th17 and Th22, and in chronic lesions, Th1 cells. Tofacitinib inhibits Th1-, Th2-, and Th17-associated cytokines by selectively blocking JAK1 and JAK3 receptors. We conducted a multicentric, retrospective chart analysis to study the efficacy and safety of tofacitinib in patients with moderate to severe refractory AD. Materials and Methods: We included 16 adult patients (aged >18 years) with moderate to severe AD who had previously undergone systemic therapy with inadequate response. In the baseline, demographic data, previous treatment history, severity scores (eczema area and severity index [EASI] and SCORing Atopic Dermatitis [SCORAD]), and quality of life score (Dermatology Life Quality Index [DLQI]) were noted. Baseline blood investigations, including complete blood count, liver function test, renal function test, lipid profile, and interferon gamma release assay for tuberculosis, were done. Patients were followed up every month for 6 months that included documentation of severity scores, blood investigations, and DLQI. Any adverse events, if reported, were noted.

Result

All 16 patients completed the 6-month trial. Our patients were previously treated with cyclosporine (n = 10), methotrexate (n = 3), or both (n = 3). The mean EASI scores improved from 23.38 ± 9.56 at baseline to 8.50 ± 7.57 at the end of 6 months. The mean SCORAD score improved from 41.25 ± 8.69 at baseline to 14.93 ± 7.82 at the end of 6 months. Quality of life also improved as the mean DLQI improved from 15.18 ± 2.73 at baseline to 5.31 ± 4.11 at the end of the study period. No severe adverse reactions were noted, but 3 patients experienced dyslipidemia and 2 patients had altered bleeding time.

Conclusion

Tofacitinib is a safe and effective treatment option for recalcitrant moderate to severe adult AD.

Schlagwörter

Stichwörter der Autor:innen

Refractorysevere atopic dermatitisstudytofacitinib

Autor:innen und Institutionen

  • From the Department of Pediatric Dermatology, Institute of Child Health, Kolkata, West Bengal, India.
  • Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India.
  • Department of Dermatology, Wizderm Specialty Clinic, Kolkata, West Bengal, India.
  • Department of Dermatology, Padmashree Dr. D Y Patil University, Navi Mumbai, Maharashtra, India.

Zitieren

APA

Dhar, S., De, A., Sarda, A., Godse, K., & Lahiri, K. (2024). Real-World Efficacy and Safety of Oral Tofacitinib in Patients with Refractory Moderate to Severe Atopic Dermatitis: A Multicenter Retrospective Study. Indian Journal of Dermatology, 69(4), 292-295. https://doi.org/10.4103/ijd.ijd_843_22

Vancouver

Dhar S, De A, Sarda A, Godse K, Lahiri K. Real-World Efficacy and Safety of Oral Tofacitinib in Patients with Refractory Moderate to Severe Atopic Dermatitis: A Multicenter Retrospective Study. Indian Journal of Dermatology. 2024;69(4):292-295. doi:10.4103/ijd.ijd_843_22

BibTeX
@article{Dhar2024,
  author = {Dhar, Sandipan and De, Abhishek and Sarda, Aarti and Godse, Kiran and Lahiri, Koushik},
  title = {Real-World Efficacy and Safety of Oral Tofacitinib in Patients with Refractory Moderate to Severe Atopic Dermatitis: A Multicenter Retrospective Study},
  journal = {Indian Journal of Dermatology},
  year = {2024},
  volume = {69},
  number = {4},
  pages = {292--295},
  doi = {10.4103/ijd.ijd_843_22}
}
Kostenlos starten →